Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Tokyo Electron | Western Digital | Pfizer | |
|---|---|---|---|
| Moat rating | narrow Integrated Report 2026 (issued 2026-09-15) documents strong positions across the line: by Tokyo Electron's own estimate it ranks No. 1 in diffusion furnaces, batch deposition, metal deposition, coater/developers, gas chemical etch and wafer probers, No. 2 in plasma etch and bonders and No. 3 in cleaning, and holds a "100% share" of coater/developers for EUV lithography; its installed base, industry-leading by its own estimate, is approximately 100,000 units, growing by approximately 4,000-6,000 units a year; and its 26,592 patents rank No. 1 in the semiconductor production equipment industry on the LexisNexis PatentSight+ database. Reported returns stayed high through a sales decline: gross profit margin stayed between 44.6% and 47.1% and ROE between 21.8% and 37.2% across fiscal 2022-2026, including fiscal 2024 when net sales fell to ¥1,830.5 billion. The share ranks, the EUV share and the installed-base lead are company estimates, not third-party data. | narrow The FY2026 10-K names Seagate and Toshiba plus NAND-based substitutes as the competition, and discloses three customers at 16%, 15% and 13% of net revenue — 44% across three cloud buyers. A cost-scale position sold into that concentration is narrow. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip The report calls its patent portfolio its "fifth strength" and says that "by supporting our other four strengths, it serves a vital role as the foundation" for medium- to long-term corporate value: 26,592 patents as of March 31, 2026, 1,415 inventions created in Japan and 345 overseas in 2025, and Clarivate Top 100 Global Innovators recognition for the fifth consecutive year. The other strengths rest on the same proprietary process know-how — co-created technology roadmaps that evaluate technologies "for the next four generations and beyond" with customers, "numerous development PORs" (process of record) in the frontend business, and the EUV coater/developer position — so proprietary process technology, reinforced by qualification in customers' process flows, is the moat source. | cost scale The filing claims 'leadership in driving areal density and cost efficiency' with a 'global manufacturing footprint' — the moat is delivered cost per terabyte. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | co leader The CEO's message describes Tokyo Electron as "one of the world's leading suppliers of semiconductor production equipment" and states a "goal of becoming number one globally" — it does not claim to be the largest supplier overall — while by its own estimate it ranks No. 1 in six charted segments (diffusion furnace, batch deposition, metal deposition, coater/developer, gas chemical etch, wafer prober), No. 2 in plasma etch and bonders, and No. 3 in cleaning. | co leader The filing's own words: 'We believe we are well-positioned in a competitive industry with our leading product portfolio' — attributed, and set against exactly two named HDD rivals. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate Gross profit margin held in a 44.6%-47.1% range over fiscal 2022-2026, including fiscal 2024's sales decline, but in fiscal 2026 it fell 1.8 points to 45.3% "due to factors such as higher raw material prices and increased labor costs" even as net sales reached a record, and the CEO lists "revising prices appropriately with respect to cost increases caused by inflation" among five initiatives needed to improve the operating margin. | weak Three customers at 44% of revenue (16/15/13%), with the filing noting the business is 'largely dependent on the buying patterns of our large Cloud customers' — buyer leverage stated plainly. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Tokyo Electron makes wafer fab equipment for what its Integrated Report 2026 calls the "four key processes necessary for semiconductor scaling: deposition, coater/developer, etch, and cleaning", plus wafer probers and bonders for test and advanced packaging. The report grounds its edge in breadth and incumbency: leading share estimates in most of its segments, an estimated 100% share of EUV coater/developers, an installed base of approximately 100,000 units, industry-leading by its own estimate, feeding a Field Solutions business that sold ¥626.0 billion of parts, services, used equipment and modifications in fiscal 2026, and the industry's largest patent portfolio. Fiscal 2026 net sales were a record ¥2,443,533 million, but gross profit margin fell 1.8 points to 45.3% on higher raw material prices and labor costs, and operating margin fell 3.1 points to 25.6% as R&D expenses rose 11.1% to ¥277,866 million. China accounted for 34.1% of fiscal 2026 net sales, down from 41.7% the year before. | Post the flash separation, Western Digital is a focused HDD supplier whose filing calls Cloud 'our largest and fastest growing end market,' selling high-capacity enterprise drives to cloud, internet and social-media infrastructure players. The same filing shows what that focus costs: three customers were 16%, 15% and 13% of net revenue in fiscal 2026, up from none above 10% in 2024 — the cloud buildout concentrated the buyer side as fast as it grew the business. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Upstream equipment supplier to chipmakers: fiscal 2026 new-equipment sales of ¥1,775.4 billion went 59% to non-memory (logic, foundry, others), 31% to DRAM and 10% to NAND; by region, China took 34.1%, South Korea 22.3% and Taiwan 20.4% of net sales. | Layer-3 mass-capacity storage; the other half of the HDD co-leadership. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bearish Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |